Valvular Heart Disease In Antiphospholipid Syndrome (Review)

The review concerns special aspects of valvular heart disease (VHD) in antiphospholipid syndrome (APS). In addition to epidemiological data and classification criteria for APS, information is provided on the prevalence, pathogenetic mechanisms, and pathomorphological features of VHD, which is characterized by verrucous endocarditis (or Libman-Sacks endocarditis), thickening of the leaflets and valve dysfunction. The main pathogenetic events of VHD are caused by the effects of antiphospholipid antibodies, local platelet aggregation, migration of inflammatory cells and deposition of immune complexes. The course of VHD in APS is often complicated by thromboembolic complications, including embolization of the cerebral arteries and coronary arteries. Diagnosis of VHD in APS is based primary on the results of echocardiography, which allows to identify leaflet thickening, verrucous vegetations and assess the function of the valve apparatus. The use of transesophageal echocardiography makes it possible to clarify the features of valvular lesions in case of inconclusive results of transthoracic echocardiography. The issues of management of patients with and VHD are discussed, with an assessment of the results of the use of antiplatelet, anticoagulant, immunosuppressive therapy and surgical correction of severe valvular pathology. Cardiac surgery is associated with an increased risk of postoperative complications due to bleeding or thrombosis, as well as mortality.

1. Arreola-Diaz R, Majluf-Cruz A, Sanchez-Torres LE, et al. The pathophysiology of the antiphospholipid syndrome: a perspective from the blood coagulation system. Clin Appl Thromb Hemost. 2022;28:10760296221088576. doi: 10.1177/10760296221088576

2. Barbhaiya M, Zuily S, Naden R, et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2023;82(10):1258-1270. doi: 10.1136/ard-2023-224609

3. Xiao M, Zhang Y, Zhang S, et al. Antiphospholipid antibodies in critically ill patients with COVID-19. Arthritis Rheumatol. 2020;72(12):1998-2004. doi: 10.1002/art.41425

4. Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, et al. Epidemiology of antiphospholipid syndrome in the general population. Curr Rheumatol Rep. 2022;23(12):85. doi: 10.1007/s11926-021-01038-2

5. Yao WC, Leong KH, Chiu LT, et al. The trends in the incidence and thrombosis-related comorbidities of antiphospholipid syndrome: a 14-year nationwide population-based study. Thromb J. 2022;20(1):50. doi: 10.1186/s12959-022-00409-8

6. APS Foundation of America, Inc. 14.11.2024 [Internet]. English. Available from: https://apsfa.org

7. Corban MT, Duarte-Garcia A, McBane RD, et al. Antiphospholipid syndrome: role of vascular endothelial cells and implications for risk stratification and targeted therapeutics. J Am Coll Cardiol. 2017;69(18):2317-2330. doi: 10.1016/j.jacc.2017.02.058

8. Nevras V, Milaras N, Katsioulis C, et al. Acute coronary syndromes in antiphospholipid syndrome-above suspicion: a systematic review. Curr Probl Cardiol. 2023;48(3):101503. doi: 10.1016/j.cpcardiol.2022.101503.

9. Tufano A, Di Minno MND, Guida A, et al. Cardiac manifestations of antiphospholipid syndrome: clinical presentation, role of cardiac imaging, and treatment strategies. Semin Thromb Hemost. 2019;45(5):468-477. doi: 10.1055/s-0039-1692702

10. Petri M. Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):415-420. doi: 10.1182/hematology.2019000046

11. Barbhaiya M, Zuily S, Ahmadzadeh Y, et al. Development of a new international antiphospholipid syndrome classification criteria phase I/II report: generation and reduction of candidate criteria. Arthritis Care Res (Hoboken). 2021;73(10):1490-1501. doi: 10.1002/acr.24520.

12. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378(21):2010-2021. doi: 10.1056/NEJMra1705454

13. Petri M. Antiphospholipid syndrome. Transl Res. 2020;225:70-81. doi: 10.1016/j.trsl.2020.04.006

14. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x

15. Jacobs L, Wauters N, Lablad Y, et al. Diagnosis and management of catastrophic antiphospholipid syndrome and the potential impact of the 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Antibodies (Basel). 2024;13(1):21. doi: 10.3390/antib13010021

16. Kolitz T, Shiber S, Sharabi I, et al. Cardiac manifestations of antiphospholipid syndrome with focus on its primary form. Front Immunol. 2019;10:941. doi: 10.3389/fimmu.2019.00941

17. Yoo BW, Lee SW, Song JJ, et al. Clinical characteristics and longterm outcomes of Libman-Sacks endocarditis in patients with systemic lupus erythematosus. Lupus. 2020;29(9):1115-1120. doi: 10.1177/0961203320930097

18. Pons I, Louro J, Sitges M, et al. Heart valve involvement in patients with antiphospholipid syndrome: a long-term followup study of a single centre. J Clin Med. 2023;12(8):2996. doi: 10.3390/jcm12082996

19. Zmaili MA, Alzubi JM, Kocyigit D, et al. A contemporary 20-year Cleveland Clinic experience of nonbacterial thrombotic endocarditis: etiology, echocardiographic imaging, management, and outcomes. Am J Med. 2021;134(3):361-369. doi: 10.1016/j.amjmed.2020.06.047

20. Venepally NR, Arsanjani R, Agasthi P, et al. A new insight into nonbacterial thrombotic endocarditis: a systematic review of cases. Anatol J Cardiol. 2022;26(10):743-749. doi: 10.5152/AnatolJCardiol.2022.1282

21. Bakhareva YuS, Maksimov VN, Chapaeva NN. Genetic aspects of non-infectious endocarditis in patients with antiphospholipid syndrome. Journal of Siberian Medical Sciences. 2022;6(2):51–61. doi: 10.31549/2542-1174-2022-6-2-51-61 [In Russian]

22. Serrano R, Pons-Estel GJ, Espinosa G, et al. Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center. Lupus. 2020;29(9):1050-1059. doi: 10.1177/0961203320933009

23. Chen S, Zhou Y, Wang C, et al. Impact of antiphospholipid antibodies on cardiac valve lesions in systemic lupus erythematosus: a systematic review and meta-analysis. Clin Exp Med. 2024;24(1):147. doi: 10.1007/s10238-024-01406-z

24. Koniari I, Siminelakis SN, Baikoussis NG, et al. Antiphospholipid syndrome; its implication in cardiovascular diseases: a review. J Cardiothorac Surg. 2010;5:101. doi: 10.1186/1749-8090-5-101

25. Mavrogeni SI, Sfikakis PP, Kitas GD, et al. Cardiac involvement in antiphospholipid syndrome: The diagnostic role of noninvasive cardiac imaging. Semin Arthritis Rheum. 2016;45(5):611-616. doi: 10.1016/j.semarthrit.2015.09.005

26. Zuily S, Huttin O, Mohamed S, et al. Valvular heart disease in antiphospholipid syndrome. Curr Rheumatol Rep. 2013;15(4):320. doi: 10.1007/s11926-013-0320-8

27. Nagy N, Bói B, Papp G, et al. Antiphospholipid antibodies are major risk factors for non-thrombotic cardiac complications in systemic lupus erythematosus. Biomedicines. 2024;12(3):530. doi: 10.3390/biomedicines12030530

28. Zuily S, Regnault V, Selton-Suty C, et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation. 2011;124(2):215-224. doi: 10.1161/CIRCULATIONAHA.111.028522

29. Denas G, Jose SP, Bracco A, et al. Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun Rev 2015;14(3):214-22. doi: 10.1016/j.autrev.2014.11.003

30. Generali E, Folci M, Selmi C, et al. Immune-mediated heart disease. Adv Exp Med Biol. 2017;1003:145-171. doi: 10.1007/978-3-319-57613-8_8

31. Ruiz D, Oates JC, Kamen DL. Antiphospholipid antibodies and heart valve disease in systemic lupus erythematosus. Am J Med Sci. 2018;355(3):293-298. doi: 10.1016/j.amjms.2017.07.007

32. Le Ho Y, Ahmad Zaidi NA, Salleh A, et al. Aortic valve surgery for aortic regurgitation caused by Libman-Sacks endocarditis in a patient with primary antiphospholipid syndrome: a case report. J Cardiothorac Surg. 2021;16(1):92. doi: 10.1186/s13019-021-01458-2

33. Bernardi M, Spadafora L, Andaloro S, et al. Management of cardiovascular complications in antiphospholipid syndrome: a narrative review with a focus on older adults. J Clin Med. 2024;13(11):3064. doi: 10.3390/jcm13113064

34. Zuo Y, Navaz S, Liang W, et al. Prevalence of antiphospholipid antibodies and association with incident cardiovascular events. JAMA Netw Open. 2023;6(4):e236530. doi: 10.1001/jamanetworkopen.2023.6530

35. Djokovic A, Stojanovich L, Kontic M, et al. Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome. Isr Med Assoc J. 2014;16(3):162-167

36. García-Torres R, Amigo MC, de la Rosa A, et al. Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings. Lupus. 1996; 5(1):56-61. doi: 10.1177/096120339600500111

37. Ziporen L, Goldberg I, Arad M, et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus. 1996; 5(3):196-205. doi: 10.1177/096120339600500306

38. Blank M, Shani A, Goldberg I, et al. Libman-Sacks endocarditis associated with antiphospholipid syndrome and infection. Thromb Res. 2004; 114(5-6):589-592. doi: 10.1016/j.thromres.2004.06.039

39. Lecompte T, Wahl D, Perret-Guillaume C, et al. Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk. Haematologica. 2007;92(5):714-5. doi: 10.3324/haematol.10577

40. Yordan-Lopez NM, Hernandez-Suarez DF, Marshall-Perez L, et al. Nonbacterial thrombotic endocarditis of the tricuspid valve in a male patient with antiphospholipid syndrome. Cureus. 2018;10(5):e2695. doi: 10.7759/cureus.2695

41. Migliorini S, Santoro C, Scatteia A, et al. A rare case of tricuspid valve Libman-Sacks endocarditis in a pregnant woman with primary antiphospholipid syndrome. J Clin Med. 2022; 11(19):5875. doi: 10.3390/jcm11195875

42. Cervera R, Tektonidou MG, Espinosa G, et al. Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria aps manifestations (i): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. 2011;20(2):165-173. doi: 10.1177/0961203310395051

43. Niznik S, Rapoport MJ, Avnery O, et al. Heart valve disease in primary antiphospholipid syndrome. Rheumatology (Oxford). 2024;63(5):1397-1402. doi: 10.1093/rheumatology/kead399

44. Nagi T, Sahu N, Usmani N, et al. Unusual presentation of isolated nonbacterial thrombotic tricuspid valve endocarditis in systemic lupus erythematosus with secondary antiphospholipid syndrome: A Case Report. J Med Cases. 2022;13(7):330-334. doi: 10.14740/jmc3950

45. Pardos-Gea J, Ordi-Ros J, Avegliano G, et al. Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients. Lupus. 2010; 19(5):575-582. doi: 10.1177/0961203309353772.

46. Morelli S, Bernardo ML, Viganego F, et al. Left-sided heart valve abnormalities and risk of ischemic cerebrovascular accidents in patients with systemic lupus erythematosus. Lupus. 2003; 12(11):805-812. doi: 10.1191/0961203303lu468oa

47. Roldan CA, Gelgand EA, Qualls CR, et al. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol. 2005;95(12):1441-1447. doi: 10.1016/j.amjcard.2005.02.010

48. Roldan CA, Gelgand EA, Qualls CR, et al. Valvular heart disease by transthoracic echocardiography is associated with focal brain injury and central neuropsychiatric systemic lupus erythematosus. Cardiology. 2007;108(4):331-337. doi: 10.1159/000099104

49. Krause I, Lev S, Fraser A, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis. 2005;64(10):1490-3. doi: 10.1136/ard.2004.032813

50. Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015; 74(6):1011-1018. doi: 10.1136/annrheumdis-2013-204838

51. Silbiger JJ. The cardiac manifestations of antiphospholipid syndrome and their echocardiographic recognition. J Am Soc Echocardiogr. 2009; 22(10):1100-1108; quiz 1195. doi: 10.1016/j.echo.2009.06.023

52. Endara SA, Dávalos GA, Fierro CH, et al. Antiphospholipid syndrome and valvular heart disease, a complex scenario of thrombotic events, a case report. J Cardiothorac Surg. 2020;15(1):275. doi: 10.1186/s13019-020-01330-9

53. Takeuchi K, Izumi T, Nanaura H, et al. Mitral valve replacement for enlarged Libman-Sacks endocarditis in a patient with persistent primary antiphospholipid syndrome and recurrent stroke: a case report. Am J Case Rep. 2023;24:e938930. doi: 10.12659/AJCR.938930

54. Roldan CA, Qualls CR, Sopko KS, et al. Transthoracic versus transesophageal echocardiography for detection of Libman-Sacks endocarditis: a randomized controlled study. J Rheumatol. 2008;35(2):224-229. PMID: 18085739

55. Shroff H, Benenstein R, Freedberg R, et al. Mitral valve Libman-Sacks endocarditis visualized by real time three-dimensional transesophageal echocardiography. Echocardiography. 2012;29(4):E100-1. doi: 10.1111/j.1540-8175.2011.01602.x

56. Capecchi M, Abbattista M, Ciavarella A, et al. Anticoagulant therapy in patients with antiphospholipid syndrome. J Clin Med. 2022;11(23):6984. doi: 10.3390/jcm11236984

57. Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64(2):504-12. doi: 10.1002/art.33340

58. Sciascia S, Sanna G, Murru V, et al. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford). 2013;52(8):1397-1403. doi: 10.1093/rheumatology/kes388

59. Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus. 2003;12(7):518-523. doi: 10.1191/0961203303lu391oa

60. Yuriditsky E, Torres J, Izmirly PM, et al. Resolution of large aortic valve vegetations in antiphospholipid syndrome treated with therapeutic anticoagulation: a report of two cases and literature review. Lupus. 2018;27(14):2269-2273. doi: 10.1177/0961203318804876

61. Arora S, Nair S, Prabhu R, et al. Role of direct oral anticoagulation agents as thromboprophylaxis in antiphospholipid syndrome. Cureus. 2021;13(10):e19009. doi: 10.7759/cureus.19009

62. Skyrme-Jones RA, Wardrop CA, Wiles CM, et al. Transesophageal echocardiographic demonstration of resolution of mitral vegetations after warfarin in a patient with the primary antiphospholipid syndrome. J Am Soc Echocardiogr. 1995;8(3):251-256. doi: 10.1016/s0894-7317(05)80034-3

63. O’Neill D, Magaldi J, Dobkins D, et al. Dissolution of intracardiac mass lesions in the primary antiphospholipid antibody syndrome. Arch Intern Med. 1995;155(3):325-327. PMID: 7832605

64. Agirbasli MA, Hansen DE, Byrd BF 3rd. Resolution of vegetations with anticoagulation after myocardial infarction in primary antiphospholipid syndrome. J Am Soc Echocardiogr. 1997; 10(8):877-880. doi: 10.1016/s0894-7317(97)70050-6

65. Ebato M, Kitai H, Kumakura H, et al. Thrombus on the tricuspid valve in a patient with primary antiphospholipid syndrome after implantation of an inferior vena cave filter. Circ J. 2002; 66(4):425-427. doi: 10.1253/circj.66.425

66. Tomcsányi J, Zsoldos A, Szabó M. Mitral and tricuspid valve thrombus in antiphospholipid syndrome. Heart. 2004;90(6):620. doi: 10.1136/hrt.2003.017434

67. Brito FA, Tofani ML, Tofani FA, et al. Limban–Sacks endocarditis and oral anticoagulation. Arg Bras Cardiol 2004;82: 381–383. doi:10.1590/S0066-782X2004000400009

68. Ruan Y, Bridges JS, Kumar K, et al. Complete resolution of a mitral valve vegetation with anticoagulation in seronegative antiphospholipid syndrome. Clin Rheumatol. 2008;27(12):1577-1579. doi: 10.1007/s10067-008-0991-0

69. Salzberg SP, Nemirovsky D, Goldman ME, et al. Aortic valve vegetation without endocarditis. Ann Thorac Surg. 2009; 88(1):267-269. doi: 10.1016/j.athoracsur.2008.10.006

70. Prashanth P, Mukhaini M. Mitral valve leaflet and free-floating left atrial thrombi with “rhupus” and antiphospholipid syndrome. Br J Cardiol 2011;18(5):241–242. doi: 10.5837/bjc.2011.007

71. Stevanović D, Mačkić D, Džambasović E, et al. Antiphospholipid syndrome associated with non-infective mitral valve endocarditis: a case report. Journal of Health Sciences. 2014;4(1), 63–67. doi: 10.17532/jhsci.2014.149

72. Rachwan RJ, Daher GE, Fares J, et al. Complete resolution of a large bicuspid aortic valve thrombus with anticoagulation in primary antiphospholipid syndrome. Front Cardiovasc Med. 2017;4:59. doi: 10.3389/fcvm.2017.00059

73. Sirinvaravong N, Rodriguez Ziccardi MC, Patnaik S, et al. Nonbacterial thrombotic endocarditis in a patient with primary antiphospholipid syndrome. Oxf Med Case Reports. 2018;2018(6):omy024. doi: 10.1093/omcr/omy024

74. Granowicz E, Chung K. Improvement of cardiac vegetations in antiphospholipid syndrome with enoxaparin and corticosteroids after rivaroxaban failure. Case Rep Hematol. 2018;2018:8097539. doi: 10.1155/2018/8097539

75. Kitano T, Sengoku K, Itotagawa E, et al. Dynamic morphological changes in Libman-Sacks endocarditis under different anticoagulation regimens. BMJ Case Rep. 2019;12(4):e229909. doi: 10.1136/bcr-2019-229909

76. Shipman J, Agasthi P, Majdalany D, et al. Near complete resolution of nonbacterial thrombotic endocarditis in a patient with antiphospholipid antibody syndrome. Anatol J Cardiol. 2020;24(2):E5-E7. doi: 10.14744/AnatolJCardiol.2020.33027

77. Haertel F, Kretzschmar D, Schulze PC, et al. Immunomodulation in antiphospholipid-antibody-associated endocarditis: a case report and review of the literature. Eur Heart J Case Rep. 2021; 5(12):ytab445. doi: 10.1093/ehjcr/ytab445

78. Bahar AR, Mishra T, Bahar Y, et al. Aortic valve vegetation due to nonbacterial thrombotic endocarditis in a patient with antiphospholipid antibody syndrome. CASE (Phila). 2024; 8(7):386-389. doi: 10.1016/j.case.2024.05.002

79. Bowden A, Walsh R, Murphy R, et al. A case of Libman-Sacks endocarditis in a patient with systemic lupus erythematosus and antiphospholipid syndrome. Eur Heart J Case Rep. 2024;8(10):ytae503. doi: 10.1093/ehjcr/ytae503

80. Mahajan K, Negi P, Merwaha R, et al. Isolated tricuspid valve Libman-Sacks endocarditis in a patient with antiphospholipid antibody syndrome. BMJ Case Rep. 2017; 2017:bcr2017219217. doi: 10.1136/bcr-2017-219217

81. Bai Z, Hou J, Ren W, et al. Diagnosis and surgical treatment for isolated tricuspid Libman-Sacks endocarditis: a rare case report and literatures review. J Cardiothorac Surg. 2015;10:93. doi: 10.1186/s13019-015-0302-1.

82. Hubben A, McCrae KR. Emerging therapies in antiphospholipid syndrome. Transfus Med Rev. 2022;36(4):195-203. doi: 10.1016/j.tmrv.2022.09.002

83. Arachchillage DJ, Laffan M, Pericleous C. Hydroxychloroquine as an immunomodulatory and antithrombotic treatment in antiphospholipid syndrome. Int J Mol Sci. 2023;24(2):1331. doi: 10.3390/ijms24021331

84. Ginanjar E, Yulianto Y. Autoimmune disease with cardiac valves involvement: Libman-Sacks endocarditis. Acta Med Indones. 2017;49(2):148-150

85. Micallef S, Mallia Azzopardi C. Antiphospholipid syndrome masquerading as a case of infective endocarditis. BMJ Case Rep. 2018;2018:bcr2018224404. doi: 10.1136/bcr-2018-224404

86. Eviatar T, Niznik S, Elkayam O, Ben-Gal Y, Shavit R, Raanani E, Agmon-Levin N, Paran D. Heart valve surgery in antiphospholipid syndrome patients-morbidity and mortality. Life (Basel). 2023;13(4):891. doi: 10.3390/life13040891

87. Roldan CA, Sibbitt WL Jr, Qualls CR, Jung RE, Greene ER, Gasparovic CM, Hayek RA, Charlton GA, Crookston K. Libman-Sacks endocarditis and embolic cerebrovascular disease. JACC Cardiovasc Imaging. 2013;6(9):973-983. doi: 10.1016/j.jcmg.2013.04.012

88. Colli A, Mestres CA, Espinosa G, Plasín MA, Pomar JL, Font J, Cervera R. Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. Eur J Cardiothorac Surg. 2010;37(1):154-158. doi: 10.1016/j.ejcts.2009.06.046

89. Hegde VA, Vivas Y, Shah H, Haybron D, Srinivasan V, Dua A, Gradman A. Cardiovascular surgical outcomes in patients with the antiphospholipid syndrome — a case-series. Heart Lung Circ. 2007;16(6):423-7. doi: 10.1016/j.hlc.2007.03.010

90. Erdozain JG, Ruiz-Irastorza G, Segura MI, Amigo MC, Espinosa G, Pomar JL, Perez-Valero I, Ateka-Barrutia O, Khamashta MA. Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care Res (Hoboken). 2012;64(8):1256-1260. doi: 10.1002/acr.21670

91. Chalvon NB, Costedoat-Chalumeau N, Pennaforte JL, et al. Severe Libman-Sacks endocarditis complicating antiphospholipid syndrome: a retrospective analysis of 23 operated cases. Rheumatology (Oxford). 2023;62(2):707-715. doi: 10.1093/rheumatology/keac315

92. Masoumi S, Parizad R, Parvizi R, et al. Recurrence of valvular involvement in Libman-Sacks endocarditis associated with antiphospholipid syndrome: A case report. Clin Case Rep. 2024; 12(9): e9352. doi: 10.1002/ccr3.9352

93. Gorki H, Malinovski V, Stanbridge RD. The antiphospholipid syndrome and heart valve surgery. Eur J Cardiothorac Surg. 2008;33(2):168-81. doi: 10.1016/j.ejcts.2007.11.004

94. Berkun Y, Elami A, Meir K, et al. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg. 2004;127(2):414-420. doi: 10.1016/j.jtcvs.2003.07.016